Budesonide multi-matrix system formulation for treating ulcerative colitis

Su2080 Efficacy of Budesonide MMx(r) 6 mg QD for the Maintenance of Remission in Patients With Ulcerative Colitis: Results From a Phase III, 12 Month Safety and Extended use Study

(2015) William J. Sandborn et al.   GASTROENTEROLOGY

Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study

(2012) William J. Sandborn et al.   GASTROENTEROLOGY

Ulcerative Colitis

(2011) Silvio Danese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis

(2009) William J. Sandborn et al.   GASTROENTEROLOGY

Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9mg extended-release tablets in patients with active left-sided ulcerative colitis

(2009) G.R. D'Haens et al.   Journal of Crohns & Colitis

Oral budesonide for maintenance of remission of Crohn’s disease: a pooled safety analysis

(2008) G. R. LICHTENSTEIN et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS